LINAC-based SBRT in treating early-stage NSCLC patients-single institution experience and survival data analysis

Conclusion: In the treatment of early-stage NSCLC, LINAC-based SBRT can be a feasible alternative to surgery. Although we reported worse OS data in our patient cohort compared to the literature, the higher older average age and the initial worse general condition (ECOG1-2) in our patient cohort appear to be the reason for this difference. With the comparable local control and survival data and the favorable side effect profile, SBRT might be preferable over surgery in selected cases.PMID:38414671 | PMC:PMC10896905 | DOI:10.3389/pore.2024.1611589
Source: Pathology Oncology Research - Category: Pathology Authors: Source Type: research